Department of Neurological Sciences, Dino Ferrari Center, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, University of Milan, Via F. Sforza 35, 20122, Milan, Italy.
J Neurol. 2012 Feb;259(2):201-11. doi: 10.1007/s00415-011-6145-3. Epub 2011 Jun 25.
After more than one century from Alois Alzheimer and Gaetano Perusini's first report, progress has been made in understanding the pathogenic steps of Alzheimer's disease (AD), as well as in its early diagnosis. This review discusses recent findings leading to the formulation of novel criteria for diagnosis of the disease even in a preclinical phase, by using biological markers. In addition, treatment options will be discussed, with emphasis on new disease-modifying compounds and future trial design suitable to test these drugs in an early phase of the disease.
在 Alois Alzheimer 和 Gaetano Perusini 首次报告后的一个多世纪，人们在理解阿尔茨海默病 (AD) 的发病步骤以及早期诊断方面取得了进展。本综述讨论了最近的发现，这些发现导致了使用生物标志物制定新的疾病诊断标准，甚至在疾病的临床前阶段也可以使用这些标准。此外，还将讨论治疗选择，重点是新型疾病修饰化合物和未来的试验设计，以便在疾病的早期阶段测试这些药物。
